Strategic Board Growth Pepper Bio recently expanded governance with a new board member from ICONIQ Growth, signaling a push to attract strategic investors and guidance. This presents an opening to present high-value partnerships and co-development opportunities aligned with growth objectives and governance support.

Clinical Collaboration There is an emerging licensing collaboration with G1 Therapeutics in oncology, suggesting interest in joint development or licensing deals. Sales conversations could explore additional co-development arrangements, target validation services, or transomic profiling to de-risk early-stage oncology assets.

Seed Financing Momentum Pepper Bio closed a $6.5M seed round from multiple notable investors, indicating strong market interest and an appetite for breakthrough transomic technologies. This momentum can be leveraged to offer platform expansion services, pilot studies, or early-access pricing for customers exploring transomic data integration.

Transomic Advantage The company emphasizes transomic technology using phosphoproteomic data to inform drug discovery. There is a sales opportunity to position data integration, analytics tooling, and high-throughput screening services to biotech and pharma groups aiming to de-risk target selection and patient stratification.

Financial Footing With revenue under $1M and ongoing funding, Pepper Bio may pursue collaborative grants, sponsored research, and early-access contracts to monetize its technology. CDMO-like services, contract research partnerships, or sponsored platforms could convert interest into recurring revenue while supporting scale.